Your browser doesn't support javascript.
loading
[Azilsartan Medoxomil Capabilities in Arterial Hypertension and Obesity].
Vasyuk, Y A; Shupenina, E Y; Nesvetov, V V; Nesterova, E A; Golubkova, E I.
Afiliação
  • Vasyuk YA; A.I. Evdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia.
  • Shupenina EY; A.I. Evdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia.
  • Nesvetov VV; A.I. Evdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia.
  • Nesterova EA; A.I. Evdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia.
  • Golubkova EI; A.I. Evdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia.
Kardiologiia ; 56(11): 108-112, 2016 12.
Article em Ru | MEDLINE | ID: mdl-28290827
ABSTRACT
Arterial hypertension (AH) is one of the most common cardiovascular disease. Angiotensin II (AT II), the hormone of renin-angiotensin-aldosterone system, realizes its negative effects through AT 1 receptors - application point of angiotensin receptor blockers (ARB). Due to different dissociation AT 1 receptors properties some ARBs are more effective than others. Multiply multicenter randomized and observational studies approve the effectiveness and safety of azilsartan medoxomil in patients with AH 1-2 grade. Several preclinical studies have shown the additional properties of azilsartan, including increase of insulin sensitivity, cardio- and nephron protection in obesity. In our clinical case we showed the positive influence of azilsartan medoxomil on clinic and ambulatory blood pressure, 24-hour aortic stiffness parameters, longitudinal left ventricular strain in patient with AH and obesity.
Assuntos
Palavras-chave
Buscar no Google
Base de dados: MEDLINE Assunto principal: Oxidiazóis / Benzimidazóis / Bloqueadores do Receptor Tipo 1 de Angiotensina II / Hipertensão / Anti-Hipertensivos Idioma: Ru Ano de publicação: 2016 Tipo de documento: Article
Buscar no Google
Base de dados: MEDLINE Assunto principal: Oxidiazóis / Benzimidazóis / Bloqueadores do Receptor Tipo 1 de Angiotensina II / Hipertensão / Anti-Hipertensivos Idioma: Ru Ano de publicação: 2016 Tipo de documento: Article